Last reviewed · How we verify
Polyethyleneglycol
At a glance
| Generic name | Polyethyleneglycol |
|---|---|
| Also known as | Macrogol 3350, Moviprep |
| Sponsor | University of Nottingham |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study. (PHASE4)
- Efficacy of Small Bowel Preparation in Capsule Endoscopy (PHASE3)
- Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation (NA)
- Bowel Preparation May Lead to a Higher Feasibility of Intestinal Infection (EARLY_PHASE1)
- Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis (PHASE4)
- Effect of Simethicone on Screening Colonoscopy (PHASE4)
- NBF Gingival Gel Application After Impacted Lower Third Molar Surgery (NA)
- Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyethyleneglycol CI brief — competitive landscape report
- Polyethyleneglycol updates RSS · CI watch RSS
- University of Nottingham portfolio CI